NCT06214078 is a NA clinical trial of nicotinamide mononucleotide in Ulcerative Colitis Chronic Mild, sponsored by The Third Xiangya Hospital of Central South University.

Who is sponsoring NCT06214078?

NCT06214078 is sponsored by The Third Xiangya Hospital of Central South University.

What drugs are being tested in NCT06214078?

Interventions in NCT06214078: nicotinamide mononucleotide, placebo.

What condition does NCT06214078 study?

NCT06214078 studies Ulcerative Colitis Chronic Mild.

Is NCT06214078 still recruiting?

NCT06214078 is currently status unknown. Last updated 19 January 2024.

Last reviewed 2024-01-19 · How we verify

NCT06214078

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Preliminary Clinical Study of NMN Intervention in Mild Ulcerative Colitis

Status unknown NA Last updated 19 January 2024

What this trial tests

NA trial testing nicotinamide mononucleotide in Ulcerative Colitis Chronic Mild in 48 participants. Status unknown.

Timeline

1 February 2024

Primary endpoint
1 March 2025

30 July 2025

Quick facts

Lead sponsor	The Third Xiangya Hospital of Central South University
Phase	NA
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	quadruple
Primary purpose	treatment
Enrollment	48
Start date	1 February 2024
Primary completion	1 March 2025
Estimated completion	30 July 2025
Sites	1 location across China

Drugs / interventions tested

nicotinamide mononucleotide — full drug profile →
placebo

Conditions studied

Ulcerative Colitis Chronic Mild — all drugs for Ulcerative Colitis Chronic Mild →

Sponsor

The Third Xiangya Hospital of Central South University

Who can join

Adults 18 to 75, any sex, with Ulcerative Colitis Chronic Mild. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The goal of this clinical trial is to compare the safety and efficacy of nicotinamide mononucleotide (NMN) and placebo in patients with mild ulcerative colitis (UC). The main question it aims to answer is Whether NMN can alleviate the intestinal pathology of UC patients, so as to play a role in UC treatment or adjuvant therapy. Participants will be randomized into two groups, an NMN group or a placebo group. Patients in the NMN group were treated with NMN intervention for 8 weeks. The placebo group received a placebo intervention for 8 weeks.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Microbiota-derived metabolites in inflammatory bowel disease.
Guggeis MA, Harris DM, Welz L, Rosenstiel P, et al · · 2025 · cited 10× · PMID 40032666 · DOI 10.1007/s00281-025-01046-9
Insights into the therapeutic strategies for aging and aging-associated diseases.
Dong R, Wu Q, Kan J, Fu C, et al · · 2026 · PMID 42225652 · DOI 10.1038/s41392-026-02662-z

Verify or expand the search:

Other trials of nicotinamide mononucleotide

Trials testing the same drug.

NCT05698771 — NAD-brain: a Pharmacokinetic Study of NAD Replenishment Therapy · Phase 1 · completed

Other recruiting trials for Ulcerative Colitis Chronic Mild

Currently open trials in the same condition.

NCT05791487 — Combination of Diet and Oral Budesonide for Ulcerative Colitis · NA · recruiting

Other The Third Xiangya Hospital of Central South University trials

Trials by the same sponsor.

NCT07353307 — A Clinical Trial Evaluating the Efficacy, Safety, and Pharmacokinetic Profile of TRD303 for Postoperative Analgesia Afte · Phase 3 · recruiting
NCT07123207 — Preliminary Clinical Study on the Effect of Bacillus Subtilis on the Efficacy of Infliximab in Patients With Crohn's Dis · NA · recruiting
NCT07034664 — IUS Predicts Guselkumab Efficacy in Patients With Moderate to Severe Crohn's Disease：a Prospective Study · recruiting
NCT07093294 — Value of IUS in Predicting Vedolizumab Efficacy and Assessing Transmural Healing in Early Crohn's Disease: A Multicenter · recruiting
NCT07039097 — A Multicenter, Prospective, Randomized, Controlled Clinical Study on the Effect of Hysteroscopic Uterine Septum Resectio · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06214078 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by The Third Xiangya Hospital of Central South University
Last refreshed: 19 January 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06214078.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing